U.S. Water Utilities Stock News

NasdaqGS:DAKT
NasdaqGS:DAKTElectronic

Daktronics OCVIBE Deal And Leadership Shift Test Rich Valuation Story

Daktronics (NasdaqGS:DAKT) has agreed to supply an integrated digital display system across the OCVIBE campus, a large mixed-use development project. The company also announced an executive leadership change, with the former Interim President and CEO moving into an advisory role. Both updates relate to Daktronics' positioning in large commercial installations and its ongoing leadership structure. Daktronics focuses on electronic scoreboards, digital signage, and large-format LED video...
NYSE:RS
NYSE:RSMetals and Mining

Reliance Dividend Hike And Buybacks Shape Future Payout Sustainability

Reliance, Inc. (NYSE:RS) raised its quarterly dividend. The company is continuing its long term share buyback program. Both actions reflect management’s current approach to capital allocation and shareholder distributions. Reliance, Inc. (NYSE:RS) operates in the metals service center space, supplying processed metal products to a wide range of end markets. In that kind of business, decisions around dividends and buybacks can matter as much to investors as day to day price moves for steel...
NYSE:DNA
NYSE:DNALife Sciences

A Look At Ginkgo Bioworks (DNA) Valuation As It Pivots To Robotics Labs And Biosecurity Divestiture

Ginkgo Bioworks Holdings (DNA) is back in focus after reporting 2025 results that combined smaller losses and lower cash burn with a clear pivot toward robotics-powered autonomous labs and a planned biosecurity divestiture. See our latest analysis for Ginkgo Bioworks Holdings. The earnings release, biosecurity divestiture plan, and new autonomous lab contracts have coincided with heavy selling, including a 30.48% 1-day share price return decline and a 26.79% 7-day share price return decline...
NYSE:HRI
NYSE:HRITrade Distributors

Herc Holdings’ Record Acquisition Puts Integration Progress And Valuation In Focus

Herc Holdings (NYSE:HRI) has completed its largest acquisition to date, expanding its equipment rental footprint across local markets. The company is now concentrating on post-merger integration, including combining operations, systems, and teams across the enlarged network. Management is prioritizing cost synergies, higher used equipment sales, and branch network changes following the closing of the deal. Herc Holdings runs a broad equipment rental business that serves construction,...
NasdaqCM:THRY
NasdaqCM:THRYSoftware

Is Thryv (THRY) Quietly Rewriting Its Story With ESOP Shares And Improving SaaS Margins?

In late February 2026, Thryv Holdings filed an US$8.15 million shelf registration for 2,179,185 common shares tied to its ESOP and reported fourth-quarter 2025 results showing quarterly sales of US$191.62 million, a net loss of US$9.66 million, and full-year 2025 sales of US$785.02 million with net income of US$0.31 million. Beyond the headline figures, the results underscored Thryv’s rapid pivot toward higher-margin SaaS and AI-powered tools, with SaaS revenue rising sharply, margins...
NasdaqGS:FTRE
NasdaqGS:FTRELife Sciences

A Look At Fortrea Holdings (FTRE) Valuation After Weak Q4 Results And Soft 2025–2026 Guidance

Fortrea Holdings (FTRE) shares came under pressure after the contract research group reported fourth quarter 2025 results with revenue and adjusted earnings below analyst forecasts, along with full year 2025 and 2026 guidance that trailed market expectations. See our latest analysis for Fortrea Holdings. At a share price of US$10.72, Fortrea has recorded a sharp 30 day share price return of a 37.13% decline and a 1 year total shareholder return of a 22.60% loss. This suggests momentum has...
NasdaqGS:NVCR
NasdaqGS:NVCRMedical Equipment

Is NovoCure (NVCR) Pricing Look Out Of Step With Recent Share Rebound

If you are looking at NovoCure and wondering whether the recent share price makes sense, this article will walk through what that price might be implying about the stock's value. The shares last closed at US$13.67, with returns of 20.3% over the past 7 days and 10.2% over 30 days, set against a 4.2% return year to date and a 28.3% decline over 1 year, and an 82.5% and 89.4% decline over 3 and 5 years respectively. Recent news coverage around NovoCure has focused on the company as a Nasdaq...
NasdaqGS:GDRX
NasdaqGS:GDRXHealthcare Services

Is GoodRx (GDRX) Using Employer Direct to Redefine Its Role in Workplace Drug Benefits?

GoodRx Holdings recently reported fourth-quarter 2025 results, issued 2026 revenue guidance of US$750 million to US$780 million, updated progress on its share buyback, filed a US$74.72 million shelf registration for an ESOP-related Class A stock offering, and disclosed several analyst rating changes. The company also launched GoodRx Employer Direct, a new program that lets employers directly subsidize high-cost drugs like GLP-1s at the pharmacy counter, potentially widening GoodRx’s role in...
NYSE:XPOF
NYSE:XPOFHospitality

Assessing Xponential Fitness (XPOF) Valuation After Weak Earnings And Lower 2026 Revenue Guidance

Xponential Fitness (XPOF) is back in focus after reporting fourth quarter and full year 2025 results, along with 2026 revenue guidance that points to a lower range than the prior year. See our latest analysis for Xponential Fitness. The earnings release and lower 2026 revenue guidance have coincided with sharp share price weakness, with a 1 day share price return of 47.08% decline and a 1 year total shareholder return of 67.75% decline. This points to fading momentum and a reassessment of...
NYSE:CTEV
NYSE:CTEVHealthcare Services

Claritev (CTEV) Is Down 42.1% After Launching $75 Million Buyback Amid Ongoing Losses - What's Changed

Claritev Corporation recently reported past fourth-quarter 2025 sales of US$246.55 million and a net loss of US$80.57 million, alongside full-year 2025 sales of US$965.41 million and a net loss of US$284.28 million, and announced a new share repurchase program of up to US$75 million running through 2030. While the company remains loss-making, the year-on-year reduction in losses and the commitment to buying back shares suggest management is focused on improving financial discipline and...
NasdaqGS:LINE
NasdaqGS:LINEIndustrial REITs

Is It Time To Reassess Lineage (LINE) After Recent Real Estate Sector Rethink?

If you are trying to work out whether Lineage at around US$40.52 is a bargain or just fairly priced, you are in the right place. The stock has recently posted returns of 5.8% over 7 days, 12.6% over 30 days and 14.4% year to date, although the 1 year return sits at a 29.3% decline. Recent attention on Lineage has focused on its position in the US real estate space and how investors are reassessing companies in the sector, which helps frame these recent price moves. Coverage has regularly...
NYSE:ASPN
NYSE:ASPNChemicals

A Look At Aspen Aerogels (ASPN) Valuation After Steep Losses And Manufacturing Impairment

Why Aspen Aerogels is back in focus Aspen Aerogels (ASPN) is back on investors’ radar after reporting a sharp year over year revenue decline, a large full year net loss, a sizeable impairment charge, and guidance indicating continued losses. See our latest analysis for Aspen Aerogels. The stock’s recent swings reflect this reset in expectations, with a 7 day share price return showing a 13.57% decline and a 1 year total shareholder return indicating a 59% loss, highlighting how pressure has...
NYSE:AS
NYSE:ASLuxury

Is Amer Sports (AS) Pricing In Too Much Optimism After Recent Share Price Swings?

If you are wondering whether Amer Sports at around US$37.98 is offering good value or not, you are not alone. This article is here to unpack that question clearly. The stock has had a mixed run, with a 9.5% decline over the last 7 days, a 3.7% gain over the past month, and a 27.1% return over the last year, which can change how investors think about both upside and risk. Recent news coverage has focused on Amer Sports as a consumer durables name that investors are watching for how it...
NYSE:SDRL
NYSE:SDRLEnergy Services

Seadrill’s Record Safety And Contract Wins Set Stage For 2026 Earnings

Seadrill (NYSE:SDRL) reported record operational and safety performance, marking its best safety results to date. The company secured several long term contracts, including a key award in Malaysia in the deepwater segment. Management highlighted strong execution on complex offshore projects alongside ongoing market challenges such as high reactivation costs and regional softness. At a share price of $43.88, Seadrill is drawing attention as it pairs operational execution with what the...
NasdaqGS:CBSH
NasdaqGS:CBSHBanks

Waterford Advisors Sparks Fresh Look At Commerce Bancshares Valuation And Dividends

Waterford Advisors, LLC has opened a significant new position in Commerce Bancshares, indicating fresh institutional interest in the bank. The move highlights investor focus on NasdaqGS:CBSH during a period of weaker recent share price performance. Commerce Bancshares continues to be associated with a strong capital position and a track record of consistent dividend increases. Commerce Bancshares, traded as NasdaqGS:CBSH, last closed at $50.99, with the share price showing declines of 5.6%...
NasdaqGM:RDNT
NasdaqGM:RDNTHealthcare

Is It Too Late To Reassess RadNet (RDNT) After Its Strong Multi Year Share Price Run

If you are wondering whether RadNet's share price still reflects fair value after a strong multi year run, you are not alone. This article will walk through what the numbers actually say. RadNet recently closed at US$69.81, with returns of a 0.4% decline over 7 days, a 2.6% decline over 30 days, a 1.6% decline year to date, and a 25.9% gain over 1 year, as well as a very large gain over 5 years that may have reshaped expectations around risk and opportunity. Recent news around RadNet has...
NYSE:WMK
NYSE:WMKConsumer Retailing

Weis Markets Restatement Raises Questions On Valuation And Earnings Quality

Weis Markets (NYSE:WMK) has delayed filing its annual Form 10 K as it works through a restatement of historical financial statements. The restatement is tied to errors identified in inventory accounting and related internal control issues. The company is reviewing potential material weaknesses in its financial reporting processes before submitting the updated filing. Weis Markets operates a regional supermarket chain, so reliable inventory accounting is central to how investors evaluate its...
NYSE:BHC
NYSE:BHCPharmaceuticals

Assessing Bausch Health (BHC) Valuation After Years Of Weak Returns And Ongoing Debt Reduction Efforts

Why Bausch Health Companies (BHC) Is On Investors’ Radar Today Bausch Health Companies (BHC) has come into focus after recent trading left the share price around $5.93. This has prompted investors to reassess the diversified healthcare group’s mixed return profile and current valuation signals. See our latest analysis for Bausch Health Companies. The recent pullback, with a 1 day share price return of 1.82% decline and a year to date share price return of 17.75% decline, contrasts with a 1...
NYSE:QBTS
NYSE:QBTSSoftware

Is D-Wave Quantum (QBTS) Pricing Reflect Recent Quantum Computing Headlines And Sharp Share Swings

If you are trying to figure out whether D-Wave Quantum's share price makes sense right now, you are not alone. This article looks closely at what the current market value might be telling you about the business. The stock has been volatile, with a 4% move over the last week, a 24.8% decline over 30 days, a 33.2% decline year to date, and a 242.7% return over the past year, alongside a very large return over three years and an 85.8% return over five years. Recent headlines have focused on...
NYSE:CUBE
NYSE:CUBESpecialized REITs

CubeSmart (CUBE) Margin Compression Challenges Income Focus Narrative After FY 2025 Results

CubeSmart (CUBE) has just wrapped up FY 2025 with fourth quarter revenue of US$282.7 million and basic EPS of US$0.34, while trailing twelve month revenue sits at US$1.1 billion and EPS at US$1.46, giving investors a clear read on the top and bottom line heading into the new year. Over recent periods, the company has seen revenue move from US$268.5 million and EPS of US$0.45 in Q4 2024 to US$282.7 million and EPS of US$0.34 in Q4 2025, alongside trailing twelve month EPS shifting from US$1.73...
NYSE:PK
NYSE:PKHotel and Resort REITs

Park Hotels Ties Finance And Operations With Sean Dell’Orto Promotion

Park Hotels & Resorts (NYSE:PK) has appointed Sean M. Dell’Orto as Chief Operating Officer, adding to his existing roles as Chief Financial Officer and Treasurer. The expanded role gives Dell’Orto broader oversight of operations alongside his current finance responsibilities. For Park Hotels & Resorts, which last closed at $11.31, this leadership shift puts one executive at the center of both financial and operational decisions. The stock shows mixed performance, with a 5.4% return over the...
NasdaqGS:IMCR
NasdaqGS:IMCRBiotechs

Is It Time To Reassess Immunocore (IMCR) After Recent Biotech Progress And Valuation Signals

If you are wondering whether Immunocore Holdings is priced attractively right now, this article will walk through how its current share price stacks up against several valuation checks. The stock last closed at US$32.30, with a 10.0% return over the past year but declines of 1.2% over 7 days, 2.5% over 30 days and 4.4% year to date. These movements can change how investors think about both upside potential and risk. Recent news around Immunocore has focused on its position within the...
NasdaqGS:ZD
NasdaqGS:ZDInteractive Media and Services

Ziff Davis Refocuses On Core Business As RetailMeNot Bets On Cash Back

RetailMeNot, a Ziff Davis (NasdaqGS:ZD) company, has launched a Guaranteed Cash Back program that offers assured and stackable rewards for shoppers. Ziff Davis completed its exit from the Games Publishing business in Q4 2025, refocusing on its core operations. For you as an investor, these moves sit at the heart of what Ziff Davis does today: a mix of digital media, subscription based services, and advertising supported platforms. RetailMeNot’s Guaranteed Cash Back program reflects how...
NasdaqGM:CRMD
NasdaqGM:CRMDPharmaceuticals

CorMedix Expands With Melinta Buy As Valuation Gap Draws Attention

CorMedix (NasdaqGM:CRMD) has agreed to acquire Melinta Therapeutics, adding seven approved therapies to its commercial portfolio. The transaction expands CorMedix's presence in hospital and acute care settings through a broader anti infective offering. The deal marks a shift from a single product focused model toward a multi asset commercial platform. For you as an investor, CorMedix has largely been known for its focus on infection prevention products in high risk settings. By bringing...